tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TSE:EPRX Stock Latest News

Eupraxia Pharmaceuticals price target raised to $19 from $11 at Cantor Fitzgerald
The FlyEupraxia Pharmaceuticals price target raised to $19 from $11 at Cantor Fitzgerald
9d ago
EPRX
Eupraxia Therapeutics: Positive EP-104GI EoE Data, Strong Safety Profile, and Solid Cash Runway Support Buy Rating
PremiumRatings
Eupraxia Therapeutics: Positive EP-104GI EoE Data, Strong Safety Profile, and Solid Cash Runway Support Buy Rating
16d ago
EPRX
Eupraxia Posts Strong Mid-Stage Data for Once-Yearly EoE Therapy EP-104GI
PremiumCompany Announcements
Eupraxia Posts Strong Mid-Stage Data for Once-Yearly EoE Therapy EP-104GI
16d ago
EPRX
Eupraxia reports positive data from Phase 1b/2a part of RESOLVE trial
PremiumThe Fly
Eupraxia reports positive data from Phase 1b/2a part of RESOLVE trial
16d ago
EPRX
Promising Prospects for Eupraxia Pharmaceuticals’ EP-104GI in Eosinophilic Esophagitis Treatment
PremiumRatings
Promising Prospects for Eupraxia Pharmaceuticals’ EP-104GI in Eosinophilic Esophagitis Treatment
1M ago
EPRX
Eupraxia Pharmaceuticals Reports Promising 52-Week Data for EoE Treatment
PremiumCompany AnnouncementsEupraxia Pharmaceuticals Reports Promising 52-Week Data for EoE Treatment
2M ago
6K
EPRX
Eupraxia Pharmaceuticals’ EP-104GI shows efficacy in follow-up esophagitis data
Premium
The Fly
Eupraxia Pharmaceuticals’ EP-104GI shows efficacy in follow-up esophagitis data
2M ago
EPRX
Eupraxia Pharmaceuticals: Buy Rating Backed by Strong Pipeline Advancements and Robust Financial Position
Premium
Ratings
Eupraxia Pharmaceuticals: Buy Rating Backed by Strong Pipeline Advancements and Robust Financial Position
2M ago
EPRX
Eupraxia Pharmaceuticals Releases Q3 2025 Financial Results
PremiumCompany Announcements
Eupraxia Pharmaceuticals Releases Q3 2025 Financial Results
3M ago
6K
EPRX
Eupraxia Pharmaceuticals Advances EoE Treatment with EP-104GI Trial
PremiumCompany Announcements
Eupraxia Pharmaceuticals Advances EoE Treatment with EP-104GI Trial
3M ago
EPRX
Eupraxia Pharmaceuticals management to meet virtually with Craig-Hallum
PremiumThe Fly
Eupraxia Pharmaceuticals management to meet virtually with Craig-Hallum
3M ago
EPRX
Promising Phase 2b Advancement of EP-104GI Boosts Buy Rating Amid Positive RESOLVE Trial Results
PremiumRatings
Promising Phase 2b Advancement of EP-104GI Boosts Buy Rating Amid Positive RESOLVE Trial Results
4M ago
EPRX
Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion
PremiumCompany AnnouncementsEupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion
4M ago
6K
EPRX
Closing Bell Movers: Progress Software up 4%, Jefferies slips 1% on earnings
Premium
The Fly
Closing Bell Movers: Progress Software up 4%, Jefferies slips 1% on earnings
4M ago
IDT
JEF
Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering
Premium
Company Announcements
Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering
4M ago
6K
EPRX
Eupraxia announces ‘positive’ data from highest-dose cohort in RESOLVE trial
PremiumThe Fly
Eupraxia announces ‘positive’ data from highest-dose cohort in RESOLVE trial
4M ago
EPRX
Eupraxia Pharmaceuticals Secures $80.5 Million in Public Offering
PremiumCompany Announcements
Eupraxia Pharmaceuticals Secures $80.5 Million in Public Offering
4M ago
6K
EPRX
Eupraxia Pharmaceuticals Announces Major Share Offering to Boost Capital
PremiumCompany Announcements
Eupraxia Pharmaceuticals Announces Major Share Offering to Boost Capital
4M ago
6K
EPRX
Eupraxia Pharmaceuticals Prices $70 Million Public Offering
PremiumCompany Announcements
Eupraxia Pharmaceuticals Prices $70 Million Public Offering
4M ago
6K
EPRX
Eupraxia Pharmaceuticals 12.727M share Spot Secondary priced at $5.50
PremiumThe FlyEupraxia Pharmaceuticals 12.727M share Spot Secondary priced at $5.50
4M ago
EPRX
Closing Bell Movers: ACM Research up 5% after joining S&P SmallCap 600
Premium
The Fly
Closing Bell Movers: ACM Research up 5% after joining S&P SmallCap 600
4M ago
FLY
JNJ
Eupraxia Pharmaceuticals Announces Public Offering to Fund Pipeline Expansion
Premium
Company Announcements
Eupraxia Pharmaceuticals Announces Public Offering to Fund Pipeline Expansion
4M ago
6K
EPRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >